Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$22.82
-0.62-2.65%
At close: Nov 13, 4:00 PM EST
$23.01
0.190.83%
After Hours: 4:32 PM EST
Comments
Loading...
Immunovant Analyst Ratings and Price Targets | NASDAQ:IMVT | Benzinga
Immunovant Inc has a consensus price target of $34.94 based on the ratings of 21 analysts. The high is $57 issued by Piper Sandler on October 24, 2023. The low is $4 issued by Credit Suisse on May 23, 2023. The 3 most-recent analyst ratings were released by Truist Securities, JP Morgan, and HC Wainwright & Co. on October 14, 2025, September 30, 2025, and September 4, 2025, respectively. With an average price target of $28 between Truist Securities, JP Morgan, and HC Wainwright & Co., there's an implied 21.69% upside for Immunovant Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Truist Securities
JP Morgan
HC Wainwright & Co.
B of A Securities
UBS
1calculated from analyst ratings
Analyst Ratings for Immunovant
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/14/2025 | -30.47% | Truist Securities | → $16 | Initiates | → Hold | |||
09/30/2025 | 43.42% | JP Morgan | $37 → $33 | Maintains | Overweight | |||
09/04/2025 | 52.11% | HC Wainwright & Co. | $35 → $35 | Reiterates | Buy → Buy | |||
08/12/2025 | 60.8% | JP Morgan | $40 → $37 | Maintains | Overweight | |||
08/12/2025 | 30.38% | B of A Securities | $33 → $30 | Maintains | Buy | |||
07/28/2025 | -21.77% | UBS | $17 → $18 | Maintains | Neutral | |||
04/22/2025 | -26.12% | UBS | $38 → $17 | Downgrade | Buy → Neutral | |||
03/20/2025 | — | Guggenheim | — | Reiterates | Buy → Buy | |||
03/20/2025 | 43.42% | B of A Securities | $38 → $33 | Maintains | Buy | |||
03/19/2025 | 121.64% | HC Wainwright & Co. | $51 → $51 | Reiterates | Buy → Buy | |||
03/10/2025 | — | Guggenheim | — | Reiterates | Buy → Buy | |||
02/10/2025 | 91.22% | Guggenheim | $46 → $44 | Maintains | Buy | |||
02/10/2025 | 121.64% | HC Wainwright & Co. | $51 → $51 | Reiterates | Buy → Buy | |||
02/07/2025 | 121.64% | HC Wainwright & Co. | $51 → $51 | Reiterates | Buy → Buy | |||
01/15/2025 | 95.57% | B of A Securities | $48 → $45 | Maintains | Buy | |||
01/03/2025 | — | Wolfe Research | — | Downgrade | Outperform → Peer Perform | |||
12/19/2024 | 95.57% | Wells Fargo | $47 → $45 | Maintains | Overweight | |||
11/08/2024 | 121.64% | HC Wainwright & Co. | $51 → $51 | Reiterates | Buy → Buy | |||
10/10/2024 | 56.45% | Raymond James | → $36 | Reinstates | → Outperform | |||
10/09/2024 | 130.33% | Oppenheimer | $47 → $53 | Maintains | Outperform | |||
09/30/2024 | 121.64% | HC Wainwright & Co. | $51 → $51 | Reiterates | Buy → Buy | |||
09/10/2024 | 121.64% | HC Wainwright & Co. | $51 → $51 | Reiterates | Buy → Buy | |||
09/09/2024 | — | Cantor Fitzgerald | — | Reiterates | → Overweight | |||
08/13/2024 | 78.18% | UBS | $42 → $41 | Maintains | Buy | |||
08/08/2024 | 99.91% | JP Morgan | $51 → $46 | Maintains | Overweight | |||
08/07/2024 | — | Cantor Fitzgerald | — | Reiterates | → Overweight | |||
06/20/2024 | — | Cantor Fitzgerald | — | Reiterates | → Overweight | |||
06/18/2024 | — | Cantor Fitzgerald | — | Reiterates | → Overweight | |||
06/03/2024 | 99.91% | Oppenheimer | $50 → $46 | Maintains | Outperform | |||
05/30/2024 | — | Cantor Fitzgerald | — | Reiterates | → Overweight | |||
05/30/2024 | 121.64% | HC Wainwright & Co. | $51 → $51 | Reiterates | Buy → Buy | |||
03/28/2024 | 117.3% | Oppenheimer | → $50 | Initiates | → Outperform | |||
03/25/2024 | 108.6% | Truist Securities | → $48 | Reiterates | Buy → Buy | |||
03/13/2024 | 117.3% | Goldman Sachs | → $50 | Initiates | → Buy | |||
02/20/2024 | 121.64% | JP Morgan | → $51 | Initiates | → Overweight | |||
02/15/2024 | 139.03% | Wolfe Research | → $55 | Initiates | → Outperform | |||
12/21/2023 | 121.64% | B of A Securities | $49 → $51 | Maintains | Buy | |||
12/21/2023 | 121.64% | HC Wainwright & Co. | $47 → $51 | Maintains | Buy | |||
12/12/2023 | 117.3% | Deutsche Bank | → $50 | Initiates | → Buy | |||
12/01/2023 | 143.37% | UBS | $55 → $56 | Maintains | Buy | |||
11/15/2023 | 108.6% | Truist Securities | $30 → $48 | Maintains | Buy | |||
10/24/2023 | 147.72% | Piper Sandler | $28 → $57 | Maintains | Overweight | |||
10/24/2023 | 104.26% | HC Wainwright & Co. | $29 → $47 | Maintains | Buy | |||
10/16/2023 | 95.57% | Cantor Fitzgerald | $30 → $45 | Maintains | Overweight | |||
10/13/2023 | 139.03% | UBS | $18 → $55 | Upgrade | Neutral → Buy | |||
10/09/2023 | 30.38% | Cantor Fitzgerald | → $30 | Reiterates | Overweight → Overweight | |||
09/27/2023 | 108.6% | Wells Fargo | $33 → $48 | Maintains | Overweight | |||
09/27/2023 | 117.3% | Citigroup | $33 → $50 | Maintains | Buy | |||
09/27/2023 | 73.84% | Raymond James | → $40 | Upgrade | Market Perform → Outperform | |||
09/26/2023 | 30.38% | Truist Securities | → $30 | Reiterates | Buy → Buy | |||
09/22/2023 | 39.07% | Guggenheim | → $32 | Reiterates | Buy → Buy | |||
09/18/2023 | 30.38% | Cantor Fitzgerald | → $30 | Reiterates | Overweight → Overweight | |||
08/22/2023 | 30.38% | Cantor Fitzgerald | → $30 | Reiterates | Overweight → Overweight | |||
08/16/2023 | 30.38% | Truist Securities | → $30 | Reiterates | Buy → Buy | |||
08/11/2023 | 26.03% | HC Wainwright & Co. | → $29 | Reiterates | Buy → Buy | |||
08/11/2023 | 43.42% | Citigroup | $28 → $33 | Maintains | Buy | |||
07/24/2023 | 43.42% | Wells Fargo | $27 → $33 | Maintains | Overweight | |||
07/18/2023 | 47.76% | Stifel | $28 → $34 | Maintains | Buy | |||
07/18/2023 | 26.03% | HC Wainwright & Co. | $27 → $29 | Maintains | Buy | |||
05/23/2023 | 17.34% | HC Wainwright & Co. | $26 → $27 | Maintains | Buy | |||
05/23/2023 | 21.69% | B of A Securities | $26 → $28 | Maintains | Buy | |||
05/23/2023 | 39.07% | Guggenheim | $30 → $32 | Maintains | Buy | |||
05/23/2023 | -82.62% | Credit Suisse | → $4 | Reiterates | → Underperform | |||
05/23/2023 | 39.07% | Chardan Capital | $21 → $32 | Maintains | Buy | |||
05/01/2023 | 12.99% | B of A Securities | → $26 | Initiates | → Buy | |||
04/25/2023 | 21.69% | Citigroup | → $28 | Initiates | → Buy | |||
03/31/2023 | 21.69% | Piper Sandler | → $28 | Initiates | → Overweight | |||
03/30/2023 | 21.69% | Stifel | → $28 | Initiates | → Buy | |||
03/20/2023 | 12.99% | HC Wainwright & Co. | $21 → $26 | Maintains | Buy | |||
02/15/2023 | 30.38% | Cantor Fitzgerald | → $30 | Initiates | → Overweight | |||
02/13/2023 | — | Guggenheim | — | Upgrade | Neutral → Buy | |||
02/07/2023 | -8.74% | HC Wainwright & Co. | $17 → $21 | Maintains | Buy | |||
02/06/2023 | -8.74% | SVB Leerink | $14 → $21 | Maintains | Outperform | |||
02/06/2023 | -8.74% | Chardan Capital | $19 → $21 | Maintains | Buy | |||
01/03/2023 | 17.34% | Wells Fargo | $10 → $27 | Upgrade | Equal-Weight → Overweight |
FAQ
What is the target price for Immunovant (IMVT) stock?
The latest price target for Immunovant (NASDAQ:IMVT) was reported by Truist Securities on October 14, 2025. The analyst firm set a price target for $16.00 expecting IMVT to fall to within 12 months (a possible -30.47% downside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Immunovant (IMVT)?
The latest analyst rating for Immunovant (NASDAQ:IMVT) was provided by Truist Securities, and Immunovant initiated their hold rating.
When was the last upgrade for Immunovant (IMVT)?
The last upgrade for Immunovant Inc happened on October 13, 2023 when UBS raised their price target to $55. UBS previously had a neutral for Immunovant Inc.
When was the last downgrade for Immunovant (IMVT)?
The last downgrade for Immunovant Inc happened on April 22, 2025 when UBS changed their price target from $38 to $17 for Immunovant Inc.
When is the next analyst rating going to be posted or updated for Immunovant (IMVT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immunovant, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immunovant was filed on October 14, 2025 so you should expect the next rating to be made available sometime around October 14, 2026.
Is the Analyst Rating Immunovant (IMVT) correct?
While ratings are subjective and will change, the latest Immunovant (IMVT) rating was a initiated with a price target of $0.00 to $16.00. The current price Immunovant (IMVT) is trading at is $23.01, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
